Physicians in India can now access multiple first-line treatment options for patients with common and relatively difficult-to-treat EGFR mutation (Exon 21 L858R) Patients in India with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations, can now benefit from monotherapy drugs